Kenneth I Zheng

List of Publications by Year
in descending order

73	3,096	318942	198040
papers	citations	23 h-index	52 g-index

75	75	75	5492
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study. Hepatobiliary Surgery and Nutrition, 2022, 11, 212-226.	0.7	4
2	Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. British Journal of Nutrition, 2022, 127, 1613-1620.	1.2	8
3	Interaction of SAMM50-rs738491, PARVB-rs5764455 and PNPLA3-rs738409 Increases Susceptibility to Nonalcoholic Steatohepatitis. Journal of Clinical and Translational Hepatology, 2022, 10, 219-229.	0.7	3
4	PNPLA3 rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2022, 10, 439-448.	0.7	1
5	Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism: Clinical and Experimental, 2022, 126, 154911.	1.5	31
6	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. Clinical and Molecular Hepatology, 2022, 28, 183-195.	4.5	6
7	J-shaped relationship between serum zinc levels and the severity of hepatic necro-inflammation in patients with MAFLD. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1259-1265.	1.1	6
8	Glycemic control predicts the risk of hepatic fibrosis in biopsy-proven NAFLD: a possible mediating role for leukemia inhibitory factor?. , 2022, 1, 30-34.		2
9	Short-Term Postoperative Use of Rivaroxaban to Prevent Radial Artery Occlusion After Transradial Coronary Procedure: The RESTORE Randomized Trial. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011555.	1.4	11
10	A Novel Predictive Model in Recognizing Severe COVID-19 and Multiorgan Injuries: Platelet-to-CRP Ratio. Canadian Journal of Infectious Diseases and Medical Microbiology, 2022, 2022, 1-7.	0.7	0
11	Lower serum copper concentrations are associated with higher prevalence of nonalcoholic steatohepatitis: a matched caseâ€“control study. European Journal of Gastroenterology and Hepatology, 2022, 34, 838-843.	0.8	3
12	FNDC5 polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. British Journal of Nutrition, 2021, 126, 813-824.	1.2	11
13	Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 204-207.	1.4	91
14	Extrapulmonary complications of COVIDâ€19: A multisystem disease?. Journal of Medical Virology, 2021, 93, 323-335.	2.5	131
15	Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 552-560.	1.1	7
16	MAFLD and risk of CKD. Metabolism: Clinical and Experimental, 2021, 115, 154433.	1.5	178
17	External Validation of the Nonalcoholic Steatohepatitis Scoring System in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease in China. Clinical Gastroenterology and Hepatology, 2021, 19, 412-413.	2.4	1
18	Non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis. The Lancet Gastroenterology and Hepatology, 2021, 6, 9-10.	3.7	6

#	Article	IF	Citations
19	Virus discharge and initial gastrointestinal involvement are inversely associated with circulating lymphocyte count in COVID-19. International Journal of Medical Sciences, 2021, 18, 1137-1142.	1.1	4
20	Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	5
21	Recommendations and Clinical Guidance for Children with Metabolic-associated Liver Disease during the COVID-19 Pandemic. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	2
22	Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. Frontiers in Endocrinology, 2021, 12, 604100.	1.5	25
23	Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. Clinical and Translational Gastroenterology, 2021, 12, e00321.	1.3	6
24	Clinical utility of the MAFLD definition. Journal of Hepatology, 2021, 74, 989-991.	1.8	48
25	TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsyâ€proven nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2925-2934.	1.4	6
26	Specific epigenetic age acceleration patterns among four molecular subtypes of gastric cancer and their prognostic value. Epigenomics, 2021, 13, 767-778.	1.0	4
27	Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsyâ€confirmed NAFLD. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 593-603.	1.4	19
28	Clinical characteristics and outcomes in patients with echocardiographic left ventricular spontaneous echo contrast. International Journal of Cardiology, 2021, 330, 245-250.	0.8	3
29	LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 452-459.	0.6	14
30	The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1822-1831.	1.1	8
31	Letter: Hepatitis B and MAFLD â€•a consilience of risk factors for hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2021, 54, 736-737.	1.9	1
32	Histological Characteristics of Non-alcoholic Steatohepatitis in NAFLD Patients With Low Degree of Hepatocyte Apoptosis. , 2021, 32, 758-764.		0
33	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. EClinicalMedicine, 2021, 41, 101145.	3.2	14
34	Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease. European Journal of Gastroenterology and Hepatology, 2021, 33, 430-435.	0.8	12
35	The uprising of metabolic dysfunction-associated fatty liver disease (MAFLD) in acute-on-chronic liver failure (ACLF). Hepatobiliary Surgery and Nutrition, 2021, 10, 857-859.	0.7	7
36	Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chinese Medical Journal, 2021, 134, 2911-2921.	0.9	21

#	Article	IF	Citations
37	Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1057-1064.	1.4	27
38	PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver International, 2020, 40, 107-119.	1.9	67
39	Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2020, 32, 80-86.	0.8	7
40	Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD. Diabetes and Metabolism, 2020, 46, 288-295.	1.4	24
41	From NAFLD to MAFLD: a â€œredefiningâ€•moment for fatty liver disease. Chinese Medical Journal, 2020, 133, 2271-2273.	0.9	79
42	COVID-19 Cross-Infection and Pressured Ulceration Among Healthcare Workers: Are We Really Protected by Respirators?. Frontiers in Medicine, 2020, 7, 571493.	1.2	4
43	Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis. Journal of Hepatology, 2020, 73, 1571-1573.	1.8	18
44	Non-invasive fibrosis assessment in non-alcoholic fatty liver disease. Chinese Medical Journal, 2020, 133, 2743-2745.	0.9	7
45	Marital status, an independent predictor for survival of gastric neuroendocrine neoplasm patients: a SEER database analysis. BMC Endocrine Disorders, 2020, 20, 111.	0.9	8
46	Abnormal liver enzymes in children and infants with <scp>COVID</scp>â€19: A narrative review of caseâ€series studies. Pediatric Obesity, 2020, 15, e12723.	1.4	18
47	Data sharing during COVID-19 pandemic: what to take away. Expert Review of Gastroenterology and Hepatology, 2020, 14, 1125-1130.	1.4	20
48	Radiomicsâ€based model for accurately distinguishing between severe acute respiratory syndrome associated coronavirus 2 (SARSâ€CoVâ€2) and influenza A infected pneumonia. MedComm, 2020, 1, 240-248.	3.1	16
49	ACE2: A Linkage for the Interplay Between COVID-19 and Decompensated Cirrhosis. American Journal of Gastroenterology, 2020, 115, 1544-1544.	0.2	14
50	When a new definition overhauls perceptions of MAFLD related cirrhosis care. Hepatobiliary Surgery and Nutrition, 2020, 9, 801-804.	0.7	22
51	Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. Journal of Hepatology, 2020, 73, 719-721.	1.8	112
52	Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut, 2020, 69, 1545-1547.	6.1	166
53	Plasma CRP level is positively associated with the severity of COVID-19. Annals of Clinical Microbiology and Antimicrobials, 2020, 19, 18.	1.7	201
54	Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes and Metabolism, 2020, 46, 335-337.	1.4	124

#	Article	IF	Citations
55	Obesity Is a Risk Factor for Greater COVID-19 Severity. Diabetes Care, 2020, 43, e72-e74.	4.3	323
56	Subclinical Acute Kidney Injury in COVID-19 Patients: A Retrospective Cohort Study. Nephron, 2020, 144, 347-350.	0.9	21
57	COVIDâ€19 and liver transplantation: Lessons learned from three reported cases. Transplant Infectious Disease, 2020, 22, e13335.	0.7	20
58	Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. Diabetes and Metabolism, 2020, 46, 505-507.	1.4	34
59	COVID-19 in a patient with chronic lymphocytic leukaemia. Lancet Haematology,the, 2020, 7, e351-e352.	2.2	66
60	Global epidemiology of lean nonâ€alcoholic fatty liver disease: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2041-2050.	1.4	67
61	Metabolicâ€associated fatty liver disease is associated with severity of COVIDâ€19. Liver International, 2020, 40, 2160-2163.	1.9	80
62	Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1820-1825.	1.1	9
63	Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications. Cancer Immunology, Immunotherapy, 2020, 69, 1057-1069.	2.0	31
64	PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. Diabetes and Metabolism, 2020, 46, 496-503.	1.4	5
65	Fatal outcome in a liver transplant recipient with COVID-19. American Journal of Transplantation, 2020, 20, 1907-1910.	2.6	77
66	Development and validation of a novel nonâ€invasive test for diagnosing fibrotic nonâ€alcoholic steatohepatitis in patients with biopsyâ€proven nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1804-1812.	1.4	15
67	Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. BMJ Open Diabetes Research and Care, 2020, 8, e001174.	1.2	21
68	Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism: Clinical and Experimental, 2020, 108, 154244.	1.5	281
69	Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-19. Metabolism: Clinical and Experimental, 2020, 108, 154249.	1.5	25
70	A Case Series of Recurrent Viral RNA Positivity in Recovered COVID-19 Chinese Patients. Journal of General Internal Medicine, 2020, 35, 2205-2206.	1.3	47
71	COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. Journal of Clinical and Translational Hepatology, 2020, 8, 1-7.	0.7	329
72	Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data. DNA and Cell Biology, 2019, 38, 1207-1222.	0.9	7

#	Article	IF	Citations
73	Metabolic Acidosis in Critically Ill Cirrhotic Patients with Acute Kidney Injury. Journal of Clinical and Translational Hepatology, 2019, 7, 1-10.	0.7	5